|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MICA |
Gene summary for MICA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MICA | Gene ID | 100507436 |
| Gene name | MHC class I polypeptide-related sequence A | |
| Gene Alias | MIC-A | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q29983 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100507436 | MICA | LZE4T | Human | Esophagus | ESCC | 8.03e-12 | 3.00e-01 | 0.0811 |
| 100507436 | MICA | LZE7T | Human | Esophagus | ESCC | 3.10e-04 | 2.55e-01 | 0.0667 |
| 100507436 | MICA | LZE20T | Human | Esophagus | ESCC | 6.46e-04 | 1.02e-01 | 0.0662 |
| 100507436 | MICA | LZE24T | Human | Esophagus | ESCC | 1.06e-08 | 2.36e-01 | 0.0596 |
| 100507436 | MICA | LZE6T | Human | Esophagus | ESCC | 7.69e-06 | 4.79e-01 | 0.0845 |
| 100507436 | MICA | P1T-E | Human | Esophagus | ESCC | 1.82e-07 | 4.01e-01 | 0.0875 |
| 100507436 | MICA | P2T-E | Human | Esophagus | ESCC | 1.42e-19 | 2.92e-01 | 0.1177 |
| 100507436 | MICA | P4T-E | Human | Esophagus | ESCC | 2.68e-27 | 6.57e-01 | 0.1323 |
| 100507436 | MICA | P5T-E | Human | Esophagus | ESCC | 3.82e-18 | 4.93e-01 | 0.1327 |
| 100507436 | MICA | P8T-E | Human | Esophagus | ESCC | 2.40e-07 | 1.59e-01 | 0.0889 |
| 100507436 | MICA | P9T-E | Human | Esophagus | ESCC | 3.55e-02 | 1.20e-01 | 0.1131 |
| 100507436 | MICA | P10T-E | Human | Esophagus | ESCC | 6.24e-16 | 2.59e-01 | 0.116 |
| 100507436 | MICA | P11T-E | Human | Esophagus | ESCC | 3.38e-26 | 7.15e-01 | 0.1426 |
| 100507436 | MICA | P12T-E | Human | Esophagus | ESCC | 2.04e-11 | 2.48e-01 | 0.1122 |
| 100507436 | MICA | P15T-E | Human | Esophagus | ESCC | 3.00e-12 | 2.94e-01 | 0.1149 |
| 100507436 | MICA | P16T-E | Human | Esophagus | ESCC | 9.04e-14 | 2.33e-01 | 0.1153 |
| 100507436 | MICA | P17T-E | Human | Esophagus | ESCC | 1.07e-07 | 3.53e-01 | 0.1278 |
| 100507436 | MICA | P19T-E | Human | Esophagus | ESCC | 6.99e-04 | 3.13e-01 | 0.1662 |
| 100507436 | MICA | P20T-E | Human | Esophagus | ESCC | 3.46e-10 | 2.51e-01 | 0.1124 |
| 100507436 | MICA | P21T-E | Human | Esophagus | ESCC | 8.03e-20 | 5.56e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
| GO:000815426 | Thyroid | PTC | actin polymerization or depolymerization | 117/5968 | 218/18723 | 1.85e-11 | 7.21e-10 | 117 |
| GO:0032984110 | Thyroid | PTC | protein-containing complex disassembly | 114/5968 | 224/18723 | 2.26e-09 | 6.33e-08 | 114 |
| GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
| GO:190321416 | Thyroid | PTC | regulation of protein targeting to mitochondrion | 33/5968 | 44/18723 | 5.20e-09 | 1.34e-07 | 33 |
| GO:190374718 | Thyroid | PTC | regulation of establishment of protein localization to mitochondrion | 36/5968 | 50/18723 | 6.68e-09 | 1.70e-07 | 36 |
| GO:003004125 | Thyroid | PTC | actin filament polymerization | 99/5968 | 191/18723 | 7.40e-09 | 1.85e-07 | 99 |
| GO:190353310 | Thyroid | PTC | regulation of protein targeting | 51/5968 | 81/18723 | 8.40e-09 | 2.07e-07 | 51 |
| GO:0051017112 | Thyroid | PTC | actin filament bundle assembly | 83/5968 | 157/18723 | 3.73e-08 | 8.18e-07 | 83 |
| GO:009887618 | Thyroid | PTC | vesicle-mediated transport to the plasma membrane | 74/5968 | 136/18723 | 4.20e-08 | 9.08e-07 | 74 |
| GO:0061572112 | Thyroid | PTC | actin filament bundle organization | 84/5968 | 161/18723 | 6.75e-08 | 1.40e-06 | 84 |
| GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
| GO:19039558 | Thyroid | PTC | positive regulation of protein targeting to mitochondrion | 24/5968 | 32/18723 | 6.76e-07 | 1.07e-05 | 24 |
| GO:190374910 | Thyroid | PTC | positive regulation of establishment of protein localization to mitochondrion | 26/5968 | 36/18723 | 7.90e-07 | 1.22e-05 | 26 |
| GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
| GO:0043281113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/5968 | 209/18723 | 1.93e-06 | 2.64e-05 | 99 |
| GO:0034446111 | Thyroid | PTC | substrate adhesion-dependent cell spreading | 58/5968 | 108/18723 | 2.07e-06 | 2.82e-05 | 58 |
| GO:2000116113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity | 108/5968 | 235/18723 | 3.99e-06 | 4.99e-05 | 108 |
| GO:006056219 | Thyroid | PTC | epithelial tube morphogenesis | 141/5968 | 325/18723 | 7.52e-06 | 8.73e-05 | 141 |
| GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0516721 | Liver | HCC | Kaposi sarcoma-associated herpesvirus infection | 111/4020 | 194/8465 | 3.78e-03 | 1.16e-02 | 6.45e-03 | 111 |
| hsa0516731 | Liver | HCC | Kaposi sarcoma-associated herpesvirus infection | 111/4020 | 194/8465 | 3.78e-03 | 1.16e-02 | 6.45e-03 | 111 |
| hsa0516729 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
| hsa05167113 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MICA | SNV | Missense_Mutation | rs746669979 | c.173G>A | p.Arg58His | p.R58H | protein_coding | tolerated(1) | benign(0.009) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| MICA | SNV | Missense_Mutation | c.507G>C | p.Leu169Phe | p.L169F | protein_coding | tolerated(0.06) | possibly_damaging(0.624) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| MICA | insertion | Frame_Shift_Ins | novel | c.517_518insGAGAAGT | p.Ala173GlyfsTer89 | p.A173Gfs*89 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| MICA | insertion | Frame_Shift_Ins | novel | c.518_519insACTGCTGGGTGGGGGCAGGCTTG | p.Met174LeufsTer9 | p.M174Lfs*9 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| MICA | SNV | Missense_Mutation | c.360N>C | p.Glu120Asp | p.E120D | protein_coding | tolerated(0.05) | possibly_damaging(0.835) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| MICA | SNV | Missense_Mutation | novel | c.73N>T | p.Pro25Ser | p.P25S | protein_coding | tolerated(0.55) | possibly_damaging(0.887) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MICA | SNV | Missense_Mutation | novel | c.982C>A | p.Leu328Ile | p.L328I | protein_coding | tolerated_low_confidence(0.13) | benign(0.052) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MICA | SNV | Missense_Mutation | novel | c.98N>T | p.Thr33Met | p.T33M | protein_coding | deleterious(0.04) | benign(0.11) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MICA | SNV | Missense_Mutation | novel | c.545N>A | p.Ala182Asp | p.A182D | protein_coding | tolerated(0.25) | possibly_damaging(0.887) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| MICA | SNV | Missense_Mutation | novel | c.82C>T | p.Leu28Phe | p.L28F | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 100507436 | MICA | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | HSP70 | 17911639 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |